Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pegloticase Proves Promising for Gout in Patients Who Have Undergone Kidney Transplant

Michele B. Kaufman, PharmD, BCGP  |  December 8, 2021

Research has shown that gout is prevalent and severe among patients who have undergone kidney transplantation surgery. A recent study offers hope. It demonstrated that pegloticase use by adult kidney transplant recipients with uncontrolled gout may result in considerable and prolonged decreases in serum uric acid levels.1 Abdul A Abdellatif, MD, assistant professor of medicine in the Nephrology Department, Baylor College of Medicine, Houston, presented the study data in an American Society of Nephrology presentation titled Transplantation: Clinical—Unrecognized Risk Factors, Traditional Considerations and Outcomes in recognition of Kidney Week, Nov. 4–7.

Background: In 2010, the U.S. Food & Drug Administration (FDA) approved pegloticase injection (pegylated recombinant uricase; Krystexxa) to treat chronic gout in adults who are refractory to conventional therapy.2 The agent is a PEGylated uric acid specific enzyme given at a dose of 8 mg every two weeks via intravenous infusion.3 Transplant recipients were not included in pegloticase’s pre-marketing clinical trials for FDA approval.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Important note: Pegloticase carries a Boxed Warning regarding anaphylaxis and infusion reactions, glucose 6-phosphate dehydrogenase deficiency (G6PD) deficiency-associated hemolysis, and methemoglobinemia. Pegloticase is contraindicated in patients with G6PD. Additionally, to minimize the risk of infusion reactions and/or anaphylaxis, pre-infusion medications are recommended (e.g., antihistamines, corticosteroids).  Patients should be closely monitored for serious adverse events during and after pegloticase treatment.

The Study

This ongoing, phase 4 trial, known as PROTECT (NCT 04087720), is examining the efficacy and safety of pegloticase in the kidney transplant recipients who had received a kidney at least one year prior. To meet the study’s entry criteria, participants had to have: 1) serum urate levels ≥7 mg/dL; 2) an intolerance or ineffectiveness to prior urate-lowering therapy; 3) at least one of the following: tophi or chronic gouty arthritis, and at least two gout flares in past year; and 4) a functioning kidney transplant graft, which was defined as an eGFR ≥15 mL/min/1.73m2, receiving stable immunosuppressive therapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pegloticase was administered as 8 mg every two weeks for 24 weeks. The primary end point is serum uric acid response, defined as achieving and maintaining a serum uric acid level of less than 6 mg/dL for at least 80% of the time during the six-month trial (weeks 20, 21, 22, 23 and 24). Health Assessment Questionnaire (HAQ) pain (most severe=100) and HAQ-Disability Index (DI) scores were also being evaluated, as well as the incidence of adverse events.

The Results

Twenty kidney transplant patients were enrolled, and all 20 had an initial, remarkable serum urate level decrease, with the majority sustaining this response for the study duration. The patient’s ages (mean ± standard deviation [SD]) were 53.9±10.9 (mean ± SD) years, with 14.7±6.9 (mean ± SD) years since kidney transplant. At entry, the serum urate levels (mean ± SD) were 9.4±1.5 mg/dL, with a gout duration (mean ± SD) of 8.4±11.6 years. All patients were being treated with at least two immunosuppressive agents.

At the time of analysis, 10 patients had completed treatment, three had discontinued the study, two had met the serum urate monitoring rules at two consecutive visits but had discontinued pegloticase, and five patients continued to receive pegloticase therapy. At week 24, no notable changes to eGFR were identified. Also at week 24, in the 10 patients who had completed pegloticase treatment, HAQ-pain and HAQ-DI scores improved by 26.7±30.3 (baseline: 35.9±30.2) and 0.2±0.5 (baseline: 1.0±1.0), respectively.

Seven serious adverse events occurred in five individuals. These reactions included atrial fibrillation, cellulitis (N=2), diverticulitis, duodenal ulcer, localized infection and sepsis. These reactions were deemed unrelated to pegloticase administration. No anaphylaxis or infusion reactions occurred.

The use of pegloticase in kidney transplant recipients to reduce serum uric acid levels without affecting renal function is beneficial. The preliminary data presented herein show promising results in these patients, who often have high levels of serum uric acid and symptomatic gout despite prior treatment with uric acid-lowering agents, either due to intolerance or ineffectiveness.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Abdellatif AA, Kin Z, Peloso P, et al. Pegloticase for uncontrolled gout in kidney transplant recipients: Provisional data report of a multicenter, open-label, efficacy and safety study [abstract PO2117]. Presentation. American Society of Nephrology. 2021 Nov 4.
  2. BLA Approval. BL 125293/0. (Pegloticase (Krystexxa) injection FDA approval letter.) U.S. Food & Drug Administration. 2010 Sep 14.  
  3. Highlights of prescribing information: Pegloticase (Krystexxa). U.S. Food & Drug Administration. 2016 Sep.

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:Goutpegloticase

Related Articles

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Treatment Options for Severe Refractory Gout When Pegloticase Fails

    August 12, 2016

    Figure 2: DECT of hands #1 Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric…

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences